Literature DB >> 3699121

Fenoterol powder inhaler technique in children: influence of inspiratory flow rate and breath-holding.

S Pedersen, G Steffensen.   

Abstract

The bronchodilator response after three different modes of inhalation of 0.2 mg fenoterol from a fenoterol powder inhaler was assessed in ten asthmatic children in a double-blind, placebo-controlled, cross-over study. There was a small, but statistically significant increase in response when the children inhaled as fast as possible, compared with very slow inhalations (16-19 l/min), but a breath-holding pause of 10 s after the inhalation had no significant effect on bronchodilation. Peak inspiratory flow through the inhaler, measured in 150 normal children aged 3.5-15 years, showed that all the children studied were able to generate a sufficient inspiratory flow to benefit from treatment with this inhaler. It is concluded that children using a fenoterol powder inhaler should be taught to inhale as fast as possible. They need not hold their breath after the inhalation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3699121

Source DB:  PubMed          Journal:  Eur J Respir Dis        ISSN: 0106-4339


  10 in total

1.  Effects, side effects and plasma concentrations of terbutaline in adult asthmatics after inhaling from a dry powder inhaler device at different inhalation flows and volumes.

Authors:  T Engel; B Scharling; B Skovsted; J H Heinig
Journal:  Br J Clin Pharmacol       Date:  1992-04       Impact factor: 4.335

2.  Influence of inspiratory flow rate upon the effect of a Turbuhaler.

Authors:  S Pedersen; O R Hansen; G Fuglsang
Journal:  Arch Dis Child       Date:  1990-03       Impact factor: 3.791

Review 3.  The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers.

Authors:  Jeffry Weers; Andy Clark
Journal:  Pharm Res       Date:  2016-10-13       Impact factor: 4.200

Review 4.  Antiasthma drug delivery. What is on the horizon?

Authors:  J C Virchow; C Kroegel; H Matthys
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

5.  Inhaler Technique in Low-Income, Inner-City Adults with Uncontrolled Asthma.

Authors:  Patrick K Gleeson; Luzmercy Perez; A Russell Localio; Knashawn H Morales; Xiaoyan Han; Tyra Bryant-Stephens; Andrea J Apter
Journal:  J Allergy Clin Immunol Pract       Date:  2019-06-05

6.  Pulmonary deposition and clinical response of 99mTc-labelled salbutamol delivered from a novel multiple dose powder inhaler.

Authors:  M Vidgren; J Arppe; P Vidgren; L Hyvärinen; P Vainio; M Silvasti; H Tukiainen
Journal:  Pharm Res       Date:  1994-09       Impact factor: 4.200

7.  Determination of the relative bioavailability of salbutamol to the lungs following inhalation from dry powder inhaler formulations containing drug substance manufactured by supercritical fluids and micronization.

Authors:  Catherine H Richardson; Marcel de Matas; Harold Hosker; Rahul Mukherjee; Ian Wong; Henry Chrystyn
Journal:  Pharm Res       Date:  2007-05-18       Impact factor: 4.200

8.  Effect of inhaler design variables on paediatric use of dry powder inhalers.

Authors:  Anne J Lexmond; Tonnis J Kruizinga; Paul Hagedoorn; Bart L Rottier; Henderik W Frijlink; Anne H de Boer
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

Review 9.  Inhaler technique: facts and fantasies. A view from the Aerosol Drug Management Improvement Team (ADMIT).

Authors:  Mark L Levy; P N R Dekhuijzen; P J Barnes; M Broeders; C J Corrigan; B L Chawes; L Corbetta; J C Dubus; Th Hausen; F Lavorini; N Roche; J Sanchis; Omar S Usmani; J Viejo; W Vincken; Th Voshaar; G K Crompton; Soren Pedersen
Journal:  NPJ Prim Care Respir Med       Date:  2016-04-21       Impact factor: 2.871

10.  Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial.

Authors:  Pablo Altman; Luis Wehbe; Juergen Dederichs; Tadhg Guerin; Brian Ament; Miguel Cardenas Moronta; Andrea Valeria Pino; Pankaj Goyal
Journal:  BMC Pulm Med       Date:  2018-06-14       Impact factor: 3.317

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.